Trials / Recruiting
RecruitingNCT06021340
What To-be-discard Biomaterials From ART Cycles Can Tell us About the Treatment Cycle Outcome?
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Various to-be-discard material from IVF treatment cycle will be collect and examined, aiming to identify potential reasons of successful outcome or cycle failure.
Detailed description
Usually around 2/3 of IVF material will be discarded at the end of each treatment cycle, including immature oocytes, abnormal fertilized zygotes, poor grading embryos, spent culture medium, etc. Next generation sequencing will be performed for DNA / RNA analysis including the length and the quantity, RNA-seq will be applied for transcriptome profiling, and protein profile will be investigated in a pool sample. By applying various diagnostic tools against those to-be-discard biomaterials, we aim to identify potential underlying reasons of indicating either for an IVF failure or a successful cycle, and try to develop a non-invasive testing method for embryo quality check; better detection of the embryo implantation potential and eventually further increase the IVF clinical outcome.
Conditions
Timeline
- Start date
- 2023-07-04
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
- First posted
- 2023-09-01
- Last updated
- 2023-09-01
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT06021340. Inclusion in this directory is not an endorsement.